news, journals and articles from all over the world.
A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.
Read moreWhat The Study Did: Data for nearly 230,000 men were used in this study to examine variations in survival in
Read moreWhat The Study Did: Data for nearly 230,000 men were used in this study to examine variations in survival in
Read moreA secondary analysis of the Radiation Therapy Oncology Group (RTOG) 9601 phase 3 randomized clinical trial finds the benefit of hormone therapy varies depending on a patient’s PSA level.
Read more
An international team issues recommendations for managing prostate cancer patients during the COVID-19 pandemic
Read more
Highly focused, intense doses of radiation called stereotactic ablative radiation (SABR) may slow progression of disease in a subset of men with hormone-sensitive prostate cancers that have spread to a few separate sites in the body, according to results of a phase II clinical trial of the therapy.
Read moreWhat The Study Did: This randomized clinical trial compared how effectively high-dose, targeted radiation therapy versus no treatment (observation) among
Read moreWhether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to
Read moreVanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind
Read moreResults from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate
Read moreResearchers at the University of East Anglia have discovered why some prostate cancers are more aggressive, spread to different parts
Read moreAssociate Professor Anthony Leicht was part of an international group led by Professor John Saxton from Northumbria University and the
Read more